Selected research
Market Structure
Global PCSK9 Targeted Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global PCSK9 Targeted Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for PCSK9 Targeted Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for PCSK9 Targeted Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for PCSK9 Targeted Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for PCSK9 Targeted Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of PCSK9 Targeted Drugs include Amgen, Regeneron Pharmaceuticals, Novartis, Sanofi and Innovent Biologics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global PCSK9 Targeted Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of PCSK9 Targeted Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents PCSK9 Targeted Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the PCSK9 Targeted Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
PCSK9 Targeted Drugs Segment by Company
Amgen
Regeneron Pharmaceuticals
Novartis
Sanofi
Innovent Biologics
PCSK9 Targeted Drugs Segment by Type
Inclisiran
Evolocumab
Tafolecimab
Alirocumab
PCSK9 Targeted Drugs Segment by Application
Hypercholesterolemia
Combined Hyperlipidemia
Heart Disease and Stroke Prevention
Other
PCSK9 Targeted Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PCSK9 Targeted Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PCSK9 Targeted Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PCSK9 Targeted Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the PCSK9 Targeted Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of PCSK9 Targeted Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of PCSK9 Targeted Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of PCSK9 Targeted Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Inclisiran
- Evolocumab
- Tafolecimab
- Alirocumab
Applications
- Hypercholesterolemia
- Combined Hyperlipidemia
- Heart Disease and Stroke Prevention
- Other
Companies covered
- Amgen
- Regeneron Pharmaceuticals
- Novartis
- Sanofi
- Innovent Biologics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global PCSK9 Targeted Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global PCSK9 Targeted Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global PCSK9 Targeted Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global PCSK9 Targeted Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global PCSK9 Targeted Drugs Market Dynamics
- 2.1 PCSK9 Targeted Drugs Industry Trends
- 2.2 PCSK9 Targeted Drugs Industry Drivers
- 2.3 PCSK9 Targeted Drugs Industry Opportunities and Challenges
- 2.4 PCSK9 Targeted Drugs Industry Restraints
3 PCSK9 Targeted Drugs Market by Manufacturers
- 3.1 Global PCSK9 Targeted Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global PCSK9 Targeted Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global PCSK9 Targeted Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global PCSK9 Targeted Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global PCSK9 Targeted Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global PCSK9 Targeted Drugs Manufacturers, Product Type & Application
- 3.7 Global PCSK9 Targeted Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global PCSK9 Targeted Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 PCSK9 Targeted Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 PCSK9 Targeted Drugs Tier 1, Tier 2, and Tier 3
4 PCSK9 Targeted Drugs Market by Type
- 4.1 PCSK9 Targeted Drugs Type Introduction
- 4.1.1 Inclisiran
- 4.1.2 Evolocumab
- 4.1.3 Tafolecimab
- 4.1.4 Alirocumab
- 4.2 Global PCSK9 Targeted Drugs Sales by Type
- 4.2.1 Global PCSK9 Targeted Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global PCSK9 Targeted Drugs Sales by Type (2021-2032)
- 4.2.3 Global PCSK9 Targeted Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global PCSK9 Targeted Drugs Revenue by Type
- 4.3.1 Global PCSK9 Targeted Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global PCSK9 Targeted Drugs Revenue by Type (2021-2032)
- 4.3.3 Global PCSK9 Targeted Drugs Revenue Market Share by Type (2021-2032)
5 PCSK9 Targeted Drugs Market by Application
- 5.1 PCSK9 Targeted Drugs Application Introduction
- 5.1.1 Hypercholesterolemia
- 5.1.2 Combined Hyperlipidemia
- 5.1.3 Heart Disease and Stroke Prevention
- 5.1.4 Other
- 5.2 Global PCSK9 Targeted Drugs Sales by Application
- 5.2.1 Global PCSK9 Targeted Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global PCSK9 Targeted Drugs Sales by Application (2021-2032)
- 5.2.3 Global PCSK9 Targeted Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global PCSK9 Targeted Drugs Revenue by Application
- 5.3.1 Global PCSK9 Targeted Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global PCSK9 Targeted Drugs Revenue by Application (2021-2032)
- 5.3.3 Global PCSK9 Targeted Drugs Revenue Market Share by Application (2021-2032)
6 Global PCSK9 Targeted Drugs Sales by Region
- 6.1 Global PCSK9 Targeted Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global PCSK9 Targeted Drugs Sales by Region (2021-2032)
- 6.2.1 Global PCSK9 Targeted Drugs Sales by Region (2021-2026)
- 6.2.2 Global PCSK9 Targeted Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America PCSK9 Targeted Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America PCSK9 Targeted Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe PCSK9 Targeted Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe PCSK9 Targeted Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific PCSK9 Targeted Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific PCSK9 Targeted Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa PCSK9 Targeted Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa PCSK9 Targeted Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global PCSK9 Targeted Drugs Revenue by Region
- 7.1 Global PCSK9 Targeted Drugs Revenue by Region
- 7.1.1 Global PCSK9 Targeted Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global PCSK9 Targeted Drugs Revenue by Region (2021-2026)
- 7.1.3 Global PCSK9 Targeted Drugs Revenue by Region (2027-2032)
- 7.1.4 Global PCSK9 Targeted Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America PCSK9 Targeted Drugs Revenue (2021-2032)
- 7.2.2 North America PCSK9 Targeted Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe PCSK9 Targeted Drugs Revenue (2021-2032)
- 7.3.2 Europe PCSK9 Targeted Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific PCSK9 Targeted Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific PCSK9 Targeted Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa PCSK9 Targeted Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa PCSK9 Targeted Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Amgen
- 8.1.1 Amgen Company Information
- 8.1.2 Amgen Business Overview
- 8.1.3 Amgen PCSK9 Targeted Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Amgen PCSK9 Targeted Drugs Product Portfolio
- 8.1.5 Amgen Recent Developments
- 8.2 Regeneron Pharmaceuticals
- 8.2.1 Regeneron Pharmaceuticals Company Information
- 8.2.2 Regeneron Pharmaceuticals Business Overview
- 8.2.3 Regeneron Pharmaceuticals PCSK9 Targeted Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Regeneron Pharmaceuticals PCSK9 Targeted Drugs Product Portfolio
- 8.2.5 Regeneron Pharmaceuticals Recent Developments
- 8.3 Novartis
- 8.3.1 Novartis Company Information
- 8.3.2 Novartis Business Overview
- 8.3.3 Novartis PCSK9 Targeted Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Novartis PCSK9 Targeted Drugs Product Portfolio
- 8.3.5 Novartis Recent Developments
- 8.4 Sanofi
- 8.4.1 Sanofi Company Information
- 8.4.2 Sanofi Business Overview
- 8.4.3 Sanofi PCSK9 Targeted Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Sanofi PCSK9 Targeted Drugs Product Portfolio
- 8.4.5 Sanofi Recent Developments
- 8.5 Innovent Biologics
- 8.5.1 Innovent Biologics Company Information
- 8.5.2 Innovent Biologics Business Overview
- 8.5.3 Innovent Biologics PCSK9 Targeted Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Innovent Biologics PCSK9 Targeted Drugs Product Portfolio
- 8.5.5 Innovent Biologics Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 PCSK9 Targeted Drugs Value Chain Analysis
- 9.1.1 PCSK9 Targeted Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 PCSK9 Targeted Drugs Production Mode & Process
- 9.2 PCSK9 Targeted Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 PCSK9 Targeted Drugs Distributors
- 9.2.3 PCSK9 Targeted Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst